Russell Investments Group Ltd. Invests $314,000 in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Russell Investments Group Ltd. acquired a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 67,474 shares of the company's stock, valued at approximately $314,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Clearbridge Investments LLC bought a new position in shares of GoodRx in the fourth quarter valued at approximately $5,863,000. Franklin Resources Inc. bought a new stake in GoodRx during the third quarter valued at $5,675,000. Raymond James Financial Inc. bought a new position in shares of GoodRx during the 4th quarter valued at about $2,500,000. Vanguard Group Inc. lifted its position in GoodRx by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company's stock worth $38,935,000 after buying an additional 460,753 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in GoodRx by 38.7% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company's stock worth $5,714,000 after buying an additional 342,781 shares in the last quarter. Institutional investors own 63.77% of the company's stock.

GoodRx Stock Down 0.6 %

Shares of GDRX stock traded down $0.03 during midday trading on Wednesday, reaching $4.63. 641,398 shares of the stock were exchanged, compared to its average volume of 1,378,660. GoodRx Holdings, Inc. has a 1 year low of $3.82 and a 1 year high of $9.26. The firm has a market cap of $1.78 billion, a PE ratio of -154.33, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. The company's 50 day moving average is $4.56 and its two-hundred day moving average is $4.86. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.

Analysts Set New Price Targets

A number of brokerages have commented on GDRX. Truist Financial decreased their price target on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Wells Fargo & Company lowered their price target on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Tuesday. KeyCorp dropped their price target on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Finally, Citigroup decreased their price objective on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $7.84.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.